bimatoprost

In this case it's Lumigan, an Allergan glaucoma drug that has the same underlying medication called bimatoprost and side effects that include a change in eye color and thicker lashes.

Latisse Faces Patent Challenge 2010

Latisse, which Allergan plans to launch in February, represents a new use for its seven-year-old glaucoma drug, bimatoprost, which is sold under the brand name Lumigan.

Eyelash Enhancer Gains Approval 2008

The patent covering the composition of bimatoprost expires in September 2012 for both drugs.

Latisse Faces Patent Challenge 2010

The fact is that, while rare, bimatoprost has been known to darken even blue and green eyes to a permanent dark brown.

Brooke Shields touts benefits of Latisse in ad that downplays risks 2009

In fact, allergic conjunctivitis is an adverse reaction reported with the use of the active ingredient, bimatoprost ophthalmic solution.

FDA warns maker of Latisse about misleading claims 2009

Latisse (chemical name is bimatoprost) began life as the glaucoma drug Lumigan.

Drug promises fuller lashes, but at what cost? 2009

Both Latisse and Lumigan, a glaucoma drug also from Allergan, are actually bimatoprost ophthalmic solution.

FDA warns maker of Latisse about misleading claims 2009

In fact, allergic conjunctivitis is an adverse reaction reported with the use of the active ingredient, bimatoprost ophthalmic solution.

FDA warns maker of Latisse about misleading claims 2009

Because bimatoprost lowers eye pressure in glaucoma patients using Lumigan, it could have the same effect on cosmetic users of Latisse.

Drug promises fuller lashes, but at what cost? 2009

The fact is that, while rare, bimatoprost has been known to darken even blue and green eyes to a permanent dark brown.

Brooke Shields touts benefits of Latisse in ad that downplays risks 2009